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Background: In recent years, scientific research has increasingly focused on malignancies during pregnancy. However,
the development of musculoskeletal tumors during pregnancy has only been the subject of a few studies so far. The
primary aim of this study was to identify the incidence of sarcomas during pregnancy at our musculoskeletal tumor
center (MSTC). Secondarily we intended to analyze these cases and discuss possible recommendations regarding
diagnostic work-up as well as therapy on the basis of the literature.
Methods: All female patients who had been treated for soft tissue or bone sarcoma at our academic MSTC in the
period between the years 2002 and 2010 were screened retrospectively for anamnestic annotations of pregnancy
or records of pregnancy in the obstetrical database of our university hospital. The patients who met the criteria
for inclusion (diagnosed sarcoma and pregnancy) were enrolled. For every pregnant patient two age-matched
female control patients that suffered from tumors with the same histologic type were included.
Results: In the period between 2002 and 2010, 240 female patients between the age of 16 and 45 were treated
for sarcoma. In eight out of the 240 cases the tumor disease developed or progressed during pregnancy. The delay in
diagnosis was approximately eight months and turned out to be significantly higher for pregnant patients compared
to non- pregnant controls. Each woman’s tumor was misdiagnosed at least once.
Conclusions: Diagnostic follow-up of pregnant women presenting with a growing or painful mass, which is suspected
to be a musculoskeletal tumor, should be performed at a specialized tumor center. We recommend a multidisciplinary
approach and discussing all possible consequences for mother and child intensively in accordance with the
available literature.
Keywords: Pregnancy, Sarcoma, Musculoskeletal tumor, Lower extremity, RecommendationsBackground
In recent years, scientific research has increasingly fo-
cused on malignancies during pregnancy. Although sev-
eral publications provide initial evidence that pregnancy
most likely affects the growth and/or development of a
tumor, reports are scarce and further research is neces-
sary [1–3]. Cancer is reported to occur in approximately
1 per 1000 pregnant women [4–6]. As women tend to
delay pregnancy to older ages, the incidence of cancer
during pregnancy will likely increase [7]. While breast
cancer is the most common malignancy in pregnancy* Correspondence: chlodwig.kirchhoff@mri.tum.de
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© 2015 Postl et al.[5], the incidence of musculoskeletal tumors during
pregnancy is comparably low. These tumors have only
been the subject of a few studies so far. While Maxwell
et al. [8] focused on the outcome, an Israeli group [9,
10] reported on its experience in treatment of musculo-
skeletal tumors twice. Guidelines regarding the clinical
diagnostics and acceptable as well as justifiable treat-
ment of musculoskeletal tumors during pregnancy still
do not exist. Due to the rareness of tumors during preg-
nancy, guidelines could not be issued so far, but it is im-
portant to discuss these cases and to contribute data to
the literature.
Therefore, the primary aim of this study was to iden-
tify the incidence of sarcomas during pregnancy at our
musculoskeletal tumor center (MSTC). Secondarily we
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ommendations regarding diagnostic work-up as well as
therapy on the basis of the literature.
Methods
All female patients who had been treated for soft tissue
or bone sarcoma at our academic MSTC between 2002
and 2010 were screened retrospectively for anamnestic
annotations of pregnancy or records of pregnancy in the
obstetrical database of our university hospital.
The patients who met the criteria for inclusion (diag-
nosed sarcoma and pregnancy) were enrolled according
to the guidelines of Good Clinical Practice (GCP). For
every pregnant patient two age-matched female control
patients that suffered from tumors with the same histo-
logic type were included. Therefore this retrospective
case–control study was designed to have a 2:1 matching.
The study was approved by the Medical Board of Ethics
of the Technische Universitaet Muenchen (reference no.
4092/11). From each patient written informed consent
was obtained to publish their data and information. The
patient records were anonymized prior to analysis. The
previously treating institutions or private practices were
contacted to obtain the prenatal records of the patients.
Furthermore, our own database and documentations on
each patient for detailed information about the patient
and the patient’s diseases was reviewed.
The tumor staging was based on the 6th and 7th edi-
tion of the UICC TNM staging system (Union inter-
nationale contre le cancer) and the grading of the soft
tissue sarcomas was based on the FNCLCC (Fédération
Nationale des Centers de Lutte Contre le Cancer) grad-
ing system [11]. We performed statistical and mathemat-
ical calculations and analyses (such as the arithmetic
mean or percentages) with the SigmaStat software (Sig-
maStat 4.0, Systat Software Inc., Chicago, Illinois, USA).
For the comparison of continuous quantitative data the
Welch’s t-test (two-sample unpooled t-test for unequal
variances) was performed with the QuickCalcs software
(GraphPad Software, Inc. La Jolla, California, USA) after
ensuring normal distribution of data with the Kolmogorov-
Smirnov test using SigmaStat software (SigmaStat 4.0,
Systat Software Inc., Chicago, Illinois, USA). For the com-
parison of categorical data the Fisher’s test was performed




In the period between 2002 and 2010 240 female patients
between 16 and 45 years of age were treated at our MSTC
for sarcoma. Anamnestic annotation of pregnancy was
found in eight of these cases (3.3 %). The patients’ age at
the time of diagnosis ranged between 26 and 40 years,with a mean age of 30 ± 4 years. The patients gave birth to
three male and four female babies. The sex of the 8th fetus
remains unknown due to a spontaneous abortion in the
first trimester.
Sixteen control patients with the same histologic
tumor types were included. Their age ranged between 25
and 41 years with a mean age of 29 ± 4 years.
Diagnosis
Four of the eight patients noted the first symptoms or
signs of a tumor at a menstrual age of 34.5 ± 3 weeks ac-
cording to prenatal records. In four cases a precise date
for the onset of symptoms could not be determined ac-
cording to medical records, but three patients could re-
port a time period (menstrual age of 32 to 35 weeks, 14
to 18 weeks and 27 to 32 weeks). In the remaining case
the onset of symptoms could not be investigated. In all
cases pain, a growing mass or a limitation of motion was
the clinical presentation of the sarcoma. The patients
consulted an average of 4.5 ± 2.7 different doctors until
the diagnosis of sarcoma was made at our musculoskel-
etal tumor center. From the first consultation to the cor-
rect diagnosis it took a mean of 8.0 ± 2.3 months. Six of
our eight patients stated that there was a hesitancy to
perform imaging during pregnancy. In five of these cases
imaging was performed within one week postpartum. In
the remaining case imaging was delayed until six weeks
postpartum. In only one case a magnetic resonance im-
aging (MRI) exam was performed before referral to our
MSTC, while a biopsy was performed in three cases.
Three patients had undergone a biopsy before referral to
our tumor center. All of them led to a wrong diagnosis
(benign tumors) – most likely due to non-representative
tissue sampling. After performing further biopsies in our
tumor center we diagnosed the sarcomas. Unfortunately,
the disease was already advanced in two cases and we had
to perform a rotationplasty in the first and amputation
above the knee joint in the second case. Due to her con-
cerns about the fetus, one patient refused to have any
diagnostic procedure done during pregnancy (imaging,
biopsy). After delivery, a hemipelvectomy was necessary.
Each woman’s tumor was misdiagnosed at least once
(for diagnosis details see Table 1).
In all cases the sarcoma had developed at the lower
extremity. Three synovial sarcomas, one Ewing’s sarcoma,
one clear cell sarcoma (soft tissue), one chondroblastic
osteosarcoma, one liposarcoma and one fibrosarcoma
were diagnosed at our MSTC. In all cases the tumor size
was considerably large with a mean maximum dimension
of 11.1 ± 4.6 cm and a mean tumor volume of ~620 cm3.
The UICC staging results and the FNCLCC grading re-
sults show that the malignancies were mainly resected in a
comparatively late stage (for detailed tumor information
see Table 2). The control patients consulted an average of
Table 1 Diagnosis details
First symptom Pregnancy
number





birth weight; gestational age;
sex of fetus; APGAR Score
Treatment Treatment
timing
I Pain noticed in the period
between the25th to the 30th
week of pregnancya, later
tumescence
4th in 2009 Knee joint (right);
16,5x9x12




last few weeks of
pregnancy, afterwards
stable symptoms
Cesarean (due to the patients







II Pain which occurred in the
37th week of pregnancy
2nd in 2009 Fibula dist. (left);
maximum of 9 cm
Ewing’s sarcoma G3; ypT2 ◊ Walking problems which
occurred in the 39th week
Vaginal delivery; 3140 g;





III Painful swelling noticed in
the 31th week of pregnancy









Cesarean (due to the
patients wish); 3320 g;





IV Pain which appeared in the
period between the 30th to
the 33th week of pregnancya
1st in 2004 Upper ankle joint
(left); 3x2,7,x1,5
Synovial sarcoma G2; pT1b ◊ - Vaginal delivery; 3070 g;





V Pain noticed 32th week of
pregnancy










Vaginal delivery; 3450 g;





















week of abortion and
did not want to know
the sex of the fetus; dead
Resection c
VII Pain and growing mass
both noticed in the 30th
week of pregnancy
2nd in 2009 Thigh dorsal
(right); 10x9x5
Liposarcoma G2; pT2a Δ Increasing tumor
volume in pregnancy
vaginal delvery; 3200 g;
41th week; female; healthy; −
Resection 4 months
postpartum
VIII Pain, tumescencec 3rd in 2003 Foot (right); several
sarcoma focuses
Fibrosarcoma G1; pT2b Increasing pain and
tumescence until
3rd treatment
vaginal delivery; 3500 g;




of 24, 27 and
28 weeks
aPatient could only provide range of time
bOn the recommendation of the FNCLCC clear cell sarcomas should not be graded
cUnable to retrieve exact time
◊UICC TMN Staging 6TH edition 2002






























(gestational age in weeks)
I 29 27-32a 36 8 months postpartum 10 months 10 Inflammation; PVNSb No Yes (34)
II 29 39 40 11 months postpartum 12 months (354 days) 3 Osteomyelitis No No
III 26 33 40 6 months postpartum 8 months (298 days) 5 Infectious bursal disease No Yes (35)
IV 30 32-35a 38 4 months postpartum 6 months 2 No No
V 40 34 41 4 months postpartum 6 months (166 days) 3 Femoral head necrosis No No
VI 26 14-18a - c c 8 Inguinal hernia c c
VII 33 32 41 4 months postpartum 6 months (172 days) 2 Adipose tissue;
tumescence
No No
VIII 32 c 40 gestational age of 24 weeks c 4 Lymphedema, Giant cell
tumor
MRI, US Yes (24)
aPatient could only provide range of time
bPigmented villonodular synovitis
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statistically significant difference compared to the preg-
nant patients (p = 0.183) could be detected in this regard.
The time from the first consultation to the correct diagno-
sis accounted for 6.1 ± 1.9 months for controls. Therefore
the delay in diagnosis was significantly higher for pregnant
patients (p = 0.039) compared to non- pregnant controls.
The mean maximum tumor size in control patients was
7.7 ± 2.9 cm. The tumor size of pregnant patients was sig-
nificantly larger (p = 0.042) compared to the size of
tumors in control patients.
Therapy
In no case radio- or chemotherapy was administered
during the course of pregnancy. In two cases neoadju-
vant treatment was performed after delivery; one patient
received chemotherapy, and the second was treated with
radiation therapy. One patient had to be amputated
(fibrosarcoma) three times consecutively during week
22, 25 and 26 of pregnancy, because the histology re-
ports showed only marginal or intralesional resection
twice. The patient was able to give birth to a healthy in-
fant, who is eight years old and in good health today.
The remaining seven patients underwent surgery after
delivery. A limb salvage procedure was performed on
five patients. One patient had to be treated with hemi-
pelvectomy (osteosarcoma, chondrobl.), one patient was
treated with a rotationplasty (clear cell sarcoma, soft tis-
sue). Several patients received adjuvant therapy after de-
livery and surgery, three of them were treated with
radiation therapy and another three received chemother-
apy (for details regarding therapy see Table 3). Within
the control group a limb salvage procedure was per-
formed in 15 cases and a rotationplasty was performed
in one patient.
Outcome
At the time the study was conducted, seven out of eight
patients were alive. These seven patients were withoutTable 3 Therapy details










asurgery in week 24, 27 and 28 (gestational age in weeks)evidence of disease. The other patient had been re-
ferred to our clinic at a very late stage and had already
been suffering from metastases. She received adjuvant
chemo- and radiotherapy and died of disease nine
months post surgery.
The seven disease-free patients described their general
health as good and normal. Five women delivered vagi-
nally, caesarean section was performed in two cases and
spontaneous abortion was reported in one case. On
average the patients delivered in week 39, the delivery
was considered on time in six cases, whereas one baby
was born in week 36. At the time the study was con-
ducted thirteen out of sixteen control patients were alive
without evidence of disease, one was suffering from recur-
rence and two from recurrence with metastases. Accord-
ing to Fisher’s test there was no significant difference
detected between seven patients (out of eight) without evi-
dence of disease in the patient group compared to 13 con-
trol patients (out of sixteen) without evidence of disease.
Discussion
The occurrence of a malignancy during the course of
pregnancy is certainly rare but devastating. The situation
is very uncommon for medical professionals and it is a
challenge to make the right decisions at the right time.
Literature concerning these issues is scarce. Our study
adds to this body of research by presenting eight pregnant
women with a malignancy during pregnancy.
Our results highlight the problem that a suspicious
musculoskeletal mass during pregnancy presents a diag-
nostic challenge and often leads to misdiagnosis. Inter-
preting the various symptoms was challenging for the
medical professionals. This is indicated by the fact that
the period between the first consultation and the correct
diagnosis was significantly longer for pregnant patients
and by the fact that the tumors were significantly larger
compared to non-pregnant controls. The literature re-
veals that the average delay in diagnosis of musculo-
skeletal tumors is four to six months [12, 13], thisSurgical treatment Adjuvant treatment
Marginal tumor resection after delivery Radiotherapy
En-bloc Resection after delivery Chemotherapy;
Rotationplasty after delivery Chemotherapy; Radiotherapy
En-bloc resection after delivery Radiotherapy
Hemipelvectomy after delivery Chemotherapy
Resection after delivery Radiotherapy
Resection after delivery No
3 times amputation in pregnancya No
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in line with the data in the literature. In addition this
also points out that diagnoses in our series of pregnant
tumor patients were made comparably late (eight months
diagnostic interval).
The tumor size in pregnant patients was significantly
higher compared to controls in this study. Research has
shown that the size of soft tissue tumors is related to
survival and that the chance of cure is lowered by 3 % to
5 % per centimeter increase in size [14]. Recent studies
from the United Kingdom reported a mean diameter of
eight to ten cm for soft tissue sarcomas [15, 16], while
a Scandinavian report found a mean size of seven cm
and an Italian analysis stated a mean size of only six cm
[17, 18]. Therefore the tumor size of tumor in our
control group is in the range of the literature data and
the tumor size of pregnant patients in this series is
comparably high. All women except one survived al-
though the diagnostic intervals seemed increased. Com-
paring pregnant patients with controls with Fisher’s test
concerning the number of patients without evidence of
disease reveals no significant difference, however the
low number of cases of this series could have led to a
bias in this regard and the statistical analysis should
not be overestimated.
We advise that in cases where the etiology of a grow-
ing tumor mass is not clear the patient should be re-
ferred to a tumor center for diagnosis and management.
Given that there was a hesitancy to perform imaging
during pregnancy in six of our eight cases we advise
that imaging should be arranged, keeping in mind the
information gained by the study versus the fetal risks of
various exposures. Diagnosis including each imaging
modality and management of musculoskeletal tumors is
discussed in the following sections.
Diagnosis
Ultrasound
The prenatal use of ultrasound (US) imaging for fetus
screening is well established [19]. New imaging tech-
niques such as 3D US have become available in clinical
practice and they are increasingly used for gynecological
diagnostics [20]. Since this form of imaging has no side
effects it is strongly recommended for the use in diag-
nostics of soft tissue masses during pregnancy.
Magnetic resonance imaging
Although magnetic resonance imaging (MRI) has been
increasingly performed for gynecological issues in recent
years (since there is no ionizing radiation exposure for
the patients) the safety of fetal MRI has not been fully
evaluated yet [11]. Chen et al. suggest that the use of
MRI in the first trimester should be considered, but is
still preferable to any imaging involving ionizingradiation [21]. Shellock et al. state that MRI may be per-
formed (in the first trimester also) if the procedure has
the potential to improve the care of the mother or fetus
[22]. In the ‘American College of Radiology Guidance
Document for Safe MR Practices: 2007’ Kanal et al. state
that if a MRI scan is necessary during pregnancy and the
risk-benefit ratio is acceptable, it can be performed at
any stage of pregnancy [11].
MRI contrast agents should not be routinely adminis-
tered to pregnant women [23]. Since gadolinium-based
MRI contrast agents diffuse across the placental barrier
into the fetal circulation, gadolinium is contraindicated
during pregnancy [21].
Radiation exposure: X-ray and Computed Tomography
Radiation exposure should be avoided during the course
of pregnancy whenever possible. It should be taken into
account that exposure dosages vary with different image
procedures and the type of radiation beam. Radiation
shielding is essential, but very often there still remains a
considerable exposure, which arises from scattered radi-
ation within the patient [11]. The expected fetal dose
has to be calculated or should be simulated in a human-
oid phantom model as reported by Mazonakis et al. in
every case with uncertain risk for the embryo [24]. Re-
garding possible negative effects the risk of spontaneous
abortion is highest in the first two weeks [21]. At weeks
2–7 mainly gross malformations and growth restriction
were found [25].
At weeks 8–15 the fetus is most vulnerable for mental
retardation and is still at risk for gross malformations
and growth restriction [26]. The risks of mental retard-
ation and growth restriction remain at weeks 16–25.
The concentration of free iodine in more recently used
water-soluble contrast media is relatively low, but it re-
mains unclear to which extent it crosses the placenta.
Therefore, the application of iodinated contrast media
should only be performed in cases where the application
is essential for the particular radiographic procedure be-
cause of the risk of neonatal hypothyroidism [11].
Nuclear medicine
Most diagnostic nuclear medicine procedures seem ap-
plicable during pregnancy [27]. Kal and Struikmans state
that short-lived radionuclides such as technetium-99 m
would not expose the fetus to large doses of radiation
and the dose the fetus is exposed to should be lower
than 0.01 gray (Gy) [27]. However, the application of
diagnostic nuclear medicine procedures should still be
deliberated and the procedures should only be used in
cases in which the results would change treatment man-
agement during pregnancy. Their application should be
discussed multidisciplinary and usually postponed to after
the delivery.
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Grimer et al. stated in their review about diagnosing
musculoskeletal tumors during pregnancy that the pa-
tients should always be referred to a specialist center
prior to biopsy and that the biopsy should be carried out
in the center where treatment is eventually going to be
performed [28]. We have to endorse this recommenda-
tion with regard to the literature and this series.
Management
Once diagnosed, a musculoskeletal sarcoma requires care-
ful analysis and consideration whether and to which ex-
tent treatment is acceptable for both - mother and fetus.
Surgical treatment during pregnancy
Only a few case series reporting on surgical treatment of
musculoskeletal tumors during pregnancy have been
published so far [8–10]. Anesthesia of pregnant women
needs a certain preoperative assessment. It is necessary to
pay attention to the fetal and maternal physiology and to
select appropriate anesthetic techniques and supportive
postoperative care is crucial [11]. Pregnancy causes large
hemodynamic changes, which increase the cardiac work-
load. Furthermore there are vascular changes together
with an accumulation of complications caused by blood
clotting and hemorrhage [29]. These changes during preg-
nancy have to be taken into account before any surgical
treatment. Multidisciplinary prearrangement of anes-
thesiologists, surgeons and obstetricians is essential for
a successful management [30]. Obstetric surgery during
pregnancy can be performed relatively safely provided
that an anesthesiologist familiar with the physiologic
changes of pregnancy is present. After 20 weeks of gesta-
tion positioning of the patient with left lateral uterine dis-
placement is suggested to avoid aorto-caval compression
by the growing uterus during surgery [31]. Intraoperative
fetal monitoring is recommended for procedures at or
after 24 weeks of gestation, otherwise fetal viability should
be documented before and after the procedure [31].Radiotherapy and Chemotherapy
According to Kal and Struikmans most cancers can be
treated with radiotherapy even during pregnancy [27].
Pelvic cancers should not be treated with radiotherapy
during pregnancy, because of the proximity to the fetus
[27]. The dose for the fetus depends on the particular
procedure, the radiotherapy treatment hardware and the
shielding [27, 32]. In cases where radiotherapy promises
a significantly better maternal prognosis we suggest a
multidisciplinary panel discussion. This has to focus on
minimizing the risks for the fetus by taking the recent
literature on risk minimization and dose reduction into
account [32–34].According to the literature, systemic chemotherapy
should not be electively started during the first trimester
but several chemotherapeutic agents seem applicable
during the second or third trimester [35, 36]. It needs to
be stressed that chemotherapy is a treatment that re-
quires a multidisciplinary approach and it should only
be administered if absolutely necessary and with taking
current literature into account [6, 31, 35, 37, 38].
Limitations of the study
Several limitations could not be foreclosed, including a
potential inherent selection bias due to the retrospective
nature of the analysis. However, due to the absolute rare-
ness of cases with coincidence of sarcoma and pregnancy,
a prospective study is cumbersome. The collection of
cases was limited to a single institution and was based on
a relatively small number of cases, which may also have
led to bias. Therefore the power of statistics is low and the
statistical results should not be overestimated. Further
limitations are the inhomogeneous follow-up and relying
on the amnestic annotations of pregnancies voluntarily
offered by the patients. The hesitancy of some women to
provide a history of elective pregnancy termination or
early miscarriage could have led to an underestimation of
the incidence of cases.
Conclusions
Diagnostic follow-up of pregnant women presenting with a
growing or painful mass, which is suspected to be a muscu-
loskeletal tumor, should be performed at a specialized
tumor center. We recommend a multidisciplinary approach
and discussing all possible consequences for mother and
child intensively in accordance with the available literature.
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